More than
100,000*
ERLEADA patients prescribed and counting
*From September 2018 to September 2025.
IQVIA based on projected patient volumes of IQVIA National Prescription Audit (NPA) and National Sales Perspective (NSP) data 2018-September 2025.
Living with prostate cancer can feel overwhelming. You’re not alone—hear from others navigating treatment with ERLEADA (apalutamide).
Mark shares his experience with metastatic prostate cancer and how ERLEADA has helped him continue living life with his wife, Jill.
Hear Mark and Jill's prostate cancer story—from diagnosis to treatment with ERLEADA.
Chapters
PSA=prostate-specific antigen.
I always say 'living with' prostate cancer because that's what we are trying to do."
— MARK
Asking questions is part of a team effort in treatment decisions.
Asking questions is part of a team effort in treatment decisions.
When Bob Lane's prostate cancer returned and spread, taking action with ERLEADA made all the difference. Watch and learn why it's so important to stay proactive.
If you ignore your health, it will go away.”
—BOB
Patient stories reflect the real-life experiences of persons diagnosed with mCSPC who have been prescribed ERLEADA. However, individual experiences may vary. Patient stories are not necessarily representative of what another person using ERLEADA may experience. This patient was compensated for their time and participation in this video.
Your healthcare provider is the best source of information regarding your health and treatment. Consult your healthcare provider if you have questions about your type of cancer and/or your treatment.